Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas

Soft tissue sarcoma (STS) constitutes a rare group of heterogeneous malignancies. Effective treatment options for most subtypes of STS are still limited. As a result, especially in metastatic disease, prognosis is still dismal. The ligands for the activating immunoreceptor NKG2D (NKG2DL) are commonl...

Description complète

Détails bibliographiques

Auteurs principaux:	Ilona Hagelstein, Martina S. Lutz, Moritz Schmidt, Jonas S. Heitmann, Elke Malenke, Yanjun Zhou, Kim L. Clar, Hans-Georg Kopp, Gundram Jung, Helmut R. Salih, Melanie Märklin, Clemens Hinterleitner
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2021-04-01
Collection:	Frontiers in Immunology
Sujets:	sarcoma NKG2DL CD3 CD16 fusion protein mAb
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.653081/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!